Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone deacetylase 11 (HDAC11) is a unique member of the histone deacetylase family, classified as the only member of Class IV HDACs. It deacetylates lysine residues on histones and exhibits robust defattyacylase activity. It plays roles in immunomodulation, genomic stability, cell cycle progression, and nervous system development. Aberrant expression or function is linked to metabolic disorders, cancer, and other conditions. Several selective inhibitors have been developed targeting its unique enzymatic activities.
Inhibition of histone deacetylase activity, inhibition of defattyacylase activity
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone Deacetylase 11 (HDAC11).